Key Drivers
- Gross Margin
- Debt Load
- Cash Burn
AIAI Summary
BLCO now looks more like a credible operating turnaround than a broken medtech story, with broad-based revenue growth, raised guidance, and improving margins, but the stock remains a high-risk hold until those adjusted gains convert into sustained GAAP profitability and free cash flow enough to outrun its heavy leverage and litigation overhang.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross Margin
- •Debt Load
- •Cash Burn
BLCO shows solid gross margins and modest operating improvement, but persistent losses, weak interest coverage, high leverage, and ongoing cash burn keep the investment case risky.
ക
Price Behavior
Key Price Behavior Insights:
- •Choppy rebound
- •Key resistance
- •Support holding
Over the last month, BLCO remains in a sideways-to-lower trend with a choppy bounce off $15.34, but repeated failures near $16.30 keep the chart cautious until it clears $16.30 and then $16.80.
Choppy recovery after a selloff, with repeated stalls near $16.30 despite a bounce from $15.34
Sentiment & News
Key News Insights:
- •Beat and raise
- •R&D push
- •ESG emphasis
Bausch + Lomb beat Q1 expectations, raised guidance, and signaled a continued push on margins, R&D, and ESG, supporting a constructive near-term outlook.
The update is mildly positive for BLCO, as stronger execution and sustained pipeline investment improve sentiment while supporting longer-term growth
Similar Companies in Healthcare
Other companies in the same sector with AI ratings